Robotic Technology and Healthcare Spending Fueling Artificial Pancreas Device Systems Industry, says Market.us

An Artificial Pancreas Device Systems(APDS) is a set of devices that closely replicates the function of a healthy pancreas. The pancreas, an organ of the body, secretes insulin, glucagon, and digestive enzymes to help with food digestion. Insulin is a hormone that helps cells absorb glucose from the blood and use it for energy.

According to the latest report by Market.us, ” The Global Artificial Pancreas Device Systems market is expected to reach USD 4,168.1 Million in 2032, up from US$ 985.8Mn in 2020, and expected to grow at a rate of 25.9%.”

Anurag Sharma, a senior research analyst at Market.us, said, ” The artificial pancreas device systems market is driven by high per capita incomes and increasing healthcare spending. Industry growth is also being driven by smart device adoption, technological advances such as AI, and data analysis.”

Most Artificial pancreas device systems consist of three types of devices familiar to people with diabetes. They include a continuous glucose monitoring device (CGM) and an insulin pump. A blood glucose device (such as a glucose monitor) is required to calibrate the CGM.

A computer-controlled algorithm connects the CGM and insulin pump to ensure continuous communication. An Artificial pancreas system can also be called a “closed loop,” an “automated delivery system,” or an “autonomous system of glycemic control.”

The Artificial Pancreas Device System monitors glucose levels, adjusts insulin delivery to lower high glucose levels (hyperglycemia), and reduces low glucose incidence (hypoglycemia). This is done with very little or no input from patients.

FDA approved the UVA-developed Artificial Pancreas system on January 2, 2020. Also known as Control-IQ, It regulates and monitors the blood glucose levels of patients with Type 1 diabetes efficiently.

The FDA also approved the Bigfoot Biomedical Initiative on the 7th of May 2021. This was to create an insulin delivery system that is pen-like for patients who prefer injections over pumps.

The development and testing of wearable Artificial pancreas systems have been made possible by advances in algorithmic design and miniaturization, as well as the development of precise and user-friendly CGM sensor technology.

Industry players are investing heavily in R&D and increasing demand for automated systems to manage glycemic controls.

The International Diabetes Federation estimates that one in eight adults has impaired blood glucose tolerance. This ratio is predicted to increase over the forecast period.

Increasing investments by major players in R&D activities to increase their Artificial pancreas system market share will also fuel the demand. Artificial pancreas device systems will be in high demand in the coming years due to their flexibility, accuracy, and ease of use.

The sales are also fueled by rising demand for effective diabetes monitoring and minimally invasive (MI) drug delivery systems. There is a higher demand for artificial pancreas device systems due to technological advances, including developing a software-based wireless system with automated controls.

Artificial pancreas devices are also being sold due to increased demand for computerized glucose control systems and large numbers of elderly people within the target customer segment.

As diabetes management technologies like continuous subcutaneous insulin injection (CSII), and continuous glucose monitoring systems (CGM), have improved in recent years, so has the demand for artificial pancreas device systems.